Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab Plus Chemotherapy in First-line Nasopharyngeal Carcinoma
NCT04974398Phase 3Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
A Phase 3 trial of penpulimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Aug 2021; status: active, not recruiting.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04974398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974398.